Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT05694598
PHASE1
Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy
Sponsor: Shanghai Vitalgen BioPharma Co., Ltd.
View on ClinicalTrials.gov
Summary
A Multicenter, Open-Label, Non-Randomized, Uncontrolled Study of VGR-R01 in Patients with Bietti Crystalline Dystrophy.
Official title: A Phase 1 Study to Assess the Safety and Tolerability of VGR-R01 in Patients With Bietti Crystalline Dystrophy
Key Details
Gender
All
Age Range
18 Years - 69 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2023-03-27
Completion Date
2028-09-13
Last Updated
2025-12-24
Healthy Volunteers
No
Conditions
Interventions
GENETIC
VGR-R01
CYP4v2-coding gene delivered by AAV vector
Locations (1)
Shanghai Vitalgen Biopharma Co.,Ltd.
Shanghai, Shanghai Municipality, China